iSpecimen Inc. Increase (Decrease) in Accrued Liabilities
iSpecimen Inc. (ISPC) reported Increase (Decrease) in Accrued Liabilities of $28 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- iSpecimen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$24.23K.
- iSpecimen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $24.26K.
- iSpecimen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$97.64K, a 166.69% decline year-over-year.
- iSpecimen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $71.31K.
- iSpecimen Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$549.54K.
- iSpecimen Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$371.82K, a 4068.63% decline from fiscal 2023.
- iSpecimen Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $9.37K, a 98.20% decline from fiscal 2022.
- iSpecimen Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $521.43K, a 162.17% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $28.00 10-Q · filed 2026-08-14 | -$97.61K derived: sum of 3 quarters · filed 2026-08-14 | -$26.30K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $24.26K 10-Q · filed 2026-05-18 | -$73.38K derived: sum of 2 quarters · filed 2026-05-18 | -$2.06K derived: sum of 3 quarters · filed 2026-05-18 | -$174.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$97.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$26.32K derived: sum of 2 quarters · filed 2026-04-01 | -$199.01K derived: sum of 3 quarters · filed 2026-08-14 | -$549.54K 10-K · filed 2026-04-01 |
| 2025-09-30 | $71.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$101.38K derived: sum of 2 quarters · filed 2026-08-14 | -$451.91K 10-Q · filed 2025-11-17 | -$305.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$172.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$523.22K 10-Q · filed 2026-08-14 | -$376.81K derived: sum of 3 quarters · filed 2026-08-14 | -$673.63K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$350.53K 10-Q · filed 2026-05-18 | -$204.12K derived: sum of 2 quarters · filed 2026-05-18 | -$500.95K derived: sum of 3 quarters · filed 2026-05-18 | -$892.56K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $146.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$150.41K derived: sum of 2 quarters · filed 2026-04-01 | -$542.03K derived: sum of 3 quarters · filed 2026-04-01 | -$371.82K 10-K · filed 2026-04-01 |
| 2024-09-30 | -$296.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$688.44K derived: sum of 2 quarters · filed 2025-11-17 | -$518.23K 10-Q · filed 2025-11-17 | -$5.59K derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | -$391.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$221.41K 10-Q · filed 2025-08-14 | $291.24K derived: sum of 3 quarters · filed 2025-08-14 | $436.93K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $170.21K 10-Q · filed 2025-05-19 | $682.86K derived: sum of 2 quarters · filed 2025-05-19 | $828.54K derived: sum of 3 quarters · filed 2025-05-19 | $802.50K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | $512.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $658.33K derived: sum of 2 quarters · filed 2025-04-14 | $632.29K derived: sum of 3 quarters · filed 2025-04-14 | $9.37K 10-K · filed 2025-04-14 |
| 2023-09-30 | $145.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $119.65K derived: sum of 2 quarters · filed 2024-11-07 | -$503.28K 10-Q · filed 2024-11-07 | $142.40K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$26.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$648.96K 10-Q · filed 2024-08-06 | -$3.29K derived: sum of 3 quarters · filed 2024-08-06 | $248.02K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$622.93K 10-Q · filed 2024-05-07 | $22.75K derived: sum of 2 quarters · filed 2024-05-07 | $274.06K derived: sum of 3 quarters · filed 2024-05-07 | -$131.66K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $645.67K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $896.98K derived: sum of 2 quarters · filed 2024-03-13 | $491.26K derived: sum of 3 quarters · filed 2024-03-13 | $521.43K 10-K · filed 2024-03-13 |
| 2022-09-30 | $251.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$154.41K derived: sum of 2 quarters · filed 2023-11-02 | -$124.24K 10-Q · filed 2023-11-02 | -$139.57K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$405.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$375.55K 10-Q · filed 2023-08-02 | -$390.88K derived: sum of 3 quarters · filed 2023-08-02 | -$1.25M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $30.17K 10-Q · filed 2023-05-04 | $14.84K derived: sum of 2 quarters · filed 2023-05-04 | -$839.84K derived: sum of 3 quarters · filed 2023-05-04 | -$79.35K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$15.33K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | -$870.01K derived: sum of 2 quarters · filed 2023-03-30 | -$109.52K derived: sum of 3 quarters · filed 2023-03-30 | $198.89K 10-K/A · filed 2023-03-30 |
| 2021-09-30 | -$854.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$94.18K derived: sum of 2 quarters · filed 2022-11-08 | $214.23K 10-Q · filed 2022-11-08 | $366.72K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $760.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.07M 10-Q · filed 2022-08-04 | $1.22M derived: sum of 3 quarters · filed 2022-08-04 | $1.19M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $308.41K 10-Q · filed 2022-05-10 | $460.91K derived: sum of 2 quarters · filed 2022-05-10 | $433.47K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $152.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $125.06K derived: sum of 2 quarters · filed 2022-03-22 | $282.14K 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$27.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $129.64K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $157.09K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |